Listed below are the drug, biologics and medical device recalls that may impact your ASC. Although ASCA makes every attempt to ensure this information is as complete and current as possible, ASCA cannot guarantee this as an exhaustive list of every recall that may impact your business. For the most up-to-date information on drug, biologics and medical device recalls, please visit the FDA website.
Sterile Drug Products from Vital Rx, dba Atlantic Pharmacy and Compounding: FDA Alert - Lack of Sterility Assurance
UPDATED August 18, 2017
Vital Rx, Inc., dba Atlantic Pharmacy and Compounding, issued recall of all lots of all compounded injectable prescription medications to the consumer level.
August 10, 2017
The FDA is alerting health care professionals and patients not to use drug products intended to be sterile that are produced and distributed nationwide by Vital Rx, Inc., dba Atlantic Pharmacy and Compounding, Pompano Beach, Florida, due to lack of sterility assurance. During the FDA’s recent inspection of Atlantic Pharmacy, investigators observed insanitary conditions, including poor sterile production practices, which raise concerns about Atlantic Pharmacy’s ability to assure the sterility of the drug products it produces. Administration of a non-sterile product intended to be sterile may result in serious and potentially life-threatening infections or death.
ICU Medical Issues Voluntary Recall of 0.9% Sodium Chloride Injection
July 31, 2017
ICU Medical, Inc. is voluntarily recalling one lot of 0.9% Sodium Chloride Injection, USP 1000 mL to the hospital/user level due to a confirmed customer complaint of particulate matter identified as stainless steel within a single flexible container. Injection of particulate matter could potentially lead to limited adverse events such as allergic reactions, local irritation and inflammation in organs or tissues, or other serious adverse health consequences.
Potassium Phosphate and Succinylcholine by Advanced Pharma: Recall - Potential Lack of Sterility Assurance
June 22, 2017
Advanced Pharma, Inc., dba Avella of Houston, is conducting a limited, voluntary recall due to Hospira, Inc.’s June 15, 2017 recall announcement that microbial growth was detected during a routine simulation of the manufacturing process and therefore there was a lack of sterility assurance. The products being recalled by Advanced Pharma were repackaged and/or compounded at its Houston, Texas, facility using certain Hospira products. The recalled products are specific lots of Potassium Phosphate and Succinylcholine Chloride. This is a secondary recall based on a Hospira's recent recall.
Hospira Issues Voluntary Recall for Sodium Bicarbonate, Other Products Over Microbial Growth
June 15, 2017
Hospira, Inc., a Pfizer company, is voluntarily recalling 42 lots of 8.4% Sodium Bicarbonate Injection, USP 50 mL vials; 5 lots of NeutTM (Sodium Bicarbonate 4% additive solution) 5 mL vials; 5 lots of QUELICINTM (Succinylcholine Chloride Injection), USP 200 mg/10 mL vials; and 7 lots of Potassium Phosphates Injection, USP 45 mM vials to the hospital/retail level due to microbial growth detected during a routine simulation of the manufacturing process, which represents the potential introduction of microorganisms into the products.
Voluntary Recall of Vancomycin Hydrochloride for Injection, USP by Hospira
January 25, 2017
Hospira, Inc. is voluntarily recalling one lot of Vancomycin Hydrochloride for Injection, USP (NDC: 0409-6510-01, Lot 591053A, Expiry Date 1NOV2017) to the hospital/retail level due to a confirmed customer report for the presence of particulate matter within a single vial. The product is packaged in a carton containing 1x100 mL vial. The lot was distributed from August 2016 through September 2016 in the United States. If particulate is administered to a patient, it may result in local swelling, irritation of blood vessels or tissue, blockage of blood vessels and/or low-level allergic response to the particulate. The risk is reduced by the possibility of detection, as the label contains a clear statement directing the physician to visually inspect the product for particulate matter and discoloration prior to administration.